November 19, 2012
Merck (NYSE: MRK ) , a well-known dividend stock and longtime Dow component, is of interest to many investors throughout the world. However, as with any investment, there are compelling reasons to both buy and sell this stock.
In the following video, health-care analysts Max Macaluso and David Williamson take a close look at both sides of the coin and debate the importance of Merck's losing patent protection for its leading asthma drug, Singulair.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.